Trial · NCT04424901

Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19

NCT04424901, Phase 2, Terminated, UConn Health; results first posted 2023-04-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19. Trials, record NCT04424901. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04424901

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19
NCT number: NCT04424901
Status: Terminated
Phases: Phase 2
Enrollment: 41 participants, actual
Lead sponsor: UConn Health
Conditions: COVID-19 Pneumonia, Vascular Complications
Interventions: Placebo, Dipyridamole Tablets
First posted: 2020-06-11
Last updated: 2023-04-21
Results first posted: 2023-04-21
Limitations and caveats: No data obtained beyond 9 days of enrollment. If discharged from care, phone follow up limited to data provided by subject report, up to day 9.

Source ClinicalTrials.gov

Registered outcomes9

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	D-dimer	up to 9 days	Percent Change from Baseline \[Day Zero\] to last study measure (Day 3, Day 6 or Day 9)
Primary	Platelet Count	up to 9 days	Percent Change from Baseline \[Day Zero\] to last study measure (Day 3, Day 6 or Day 9)
Secondary	Viral Detection	9 days	Evaluate for a non-detection from nasopharyngeal swab and in stool
Other	Survival	9 days	Survival Status Alive
Other	Inflammatory Markers	9 days	Change in the markers CRP/Ferritin
Other	Blood Markers	9 days	Change in Lymphocyte Count/ Fibrinogen/Cardiac Troponin
Other	PT PTT	9 days	Coagulation System
Other	Pulmonary Status	9 days	Change in SpO2/ imaging
Other	Clinical Status	9 days	Change in fever, cough, sputum

Source ClinicalTrials.gov

Outcomes9

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	D-dimer	up to 9 days	Percent Change from Baseline	Percent Change of D-Dimer (ng/mL)	MEDIAN
PRIMARY	Platelet Count	up to 9 days	Percent Change (%) from Baseline	Percent Change of 10^3 Platelets/uL	MEAN
SECONDARY	Viral Detection	9 days
OTHER_PRE_SPECIFIED	Survival	9 days
OTHER_PRE_SPECIFIED	Inflammatory Markers	9 days
OTHER_PRE_SPECIFIED	Blood Markers	9 days
OTHER_PRE_SPECIFIED	PT PTT	9 days
OTHER_PRE_SPECIFIED	Pulmonary Status	9 days
OTHER_PRE_SPECIFIED	Clinical Status	9 days

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
D-dimer	Standard Care	2.99	Inter-Quartile Range -17.12 to 85.63	Percent Change of D-Dimer (ng/mL)
D-dimer	Standard Care With Dipyridamole	-10.09	Inter-Quartile Range -22.06 to 6.08	Percent Change of D-Dimer (ng/mL)
Platelet Count	Standard Care	27.45	Standard Deviation 34.94	Percent Change of 10^3 Platelets/uL
Platelet Count	Standard Care With Dipyridamole	35.48	Standard Deviation 37.52	Percent Change of 10^3 Platelets/uL

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Standard Care	21
Overall Study	STARTED	Standard Care With Dipyridamole	20
Overall Study	COMPLETED	Standard Care	4
Overall Study	COMPLETED	Standard Care With Dipyridamole	4
Overall Study	NOT COMPLETED	Standard Care	17
Overall Study	NOT COMPLETED	Standard Care With Dipyridamole	16

Source ClinicalTrials.gov

Adverse events54

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Headache	Nervous system disorders	Standard Care	5	21	5
other	Headache	Nervous system disorders	Standard Care With Dipyridamole	4	20	4
other	Fever	General disorders	Standard Care	4	21	4
other	Fever	General disorders	Standard Care With Dipyridamole	4	20	4
other	Increase Alanine Aminotransferase	Investigations	Standard Care	2	21	2
other	Increase Alanine Aminotransferase	Investigations	Standard Care With Dipyridamole	4	20	4
other	Hypoxia	Respiratory, thoracic and mediastinal disorders	Standard Care	5	21	5
other	Hypoxia	Respiratory, thoracic and mediastinal disorders	Standard Care With Dipyridamole	2	20	2
other	Increase Aspartate Aminotransferase	Investigations	Standard Care	1	21	1
other	Increase Aspartate Aminotransferase	Investigations	Standard Care With Dipyridamole	4	20	4

1 to 10 of 54Source ClinicalTrials.gov

See all 54 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Standard Care	2	21
Total, all-cause mortality	Standard Care With Dipyridamole	2	20
Total, other adverse events	Standard Care	9	21
Total, other adverse events	Standard Care With Dipyridamole	8	20
Total, serious adverse events	Standard Care	5	21
Total, serious adverse events	Standard Care With Dipyridamole	7	20

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Standard Care With Dipyridamole vs Standard Care: deaths from any cause	Trial comparisons
Standard Care With Dipyridamole vs Standard Care: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04424901

GET https://conductscience.org/api/trials/v1/NCT04424901/events?page=2

API reference For AI assistants